Request Demo
Last update 16 May 2025
SG1906
Last update 16 May 2025
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms SG 1906, SG-1906 |
Target |
Action inhibitors |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors), CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with SG1906NCT05857332
A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.
100 Clinical Results associated with SG1906
Login to view more data
100 Translational Medicine associated with SG1906
Login to view more data
100 Patents (Medical) associated with SG1906
Login to view more data
100 Deals associated with SG1906
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CLDN18.2 positive Solid Tumors | Phase 1 | China | 30 May 2023 | |
| Metastatic Solid Tumor | Phase 1 | China | 30 May 2023 | |
| Unresectable Solid Neoplasm | Phase 1 | China | 30 May 2023 | |
| CLDN18.2 Positive Advanced Malignant Solid Neoplasm | Phase 1 | United States | 31 Oct 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free